Nature Biotechnology is a peer reviewed scientific journal published monthly by the Nature Publishing Group. The chief editor is Andrew Marshall who is part of an in-house team of editors. The focus of the journal is biotechnology including research results and the commercial business sector of this field. Coverage includes the related biological, biomedical, agricultural and environmental sciences. Also of interest are the commercial, political, legal, and societal influences that affect this field.
DREAM challenge uses crowd sourcing to test the state of the art in systems biomedicine
An international study published in Nature Biotechnology presents the combined results of a 2013 DREAM Challenge: a crowd-sourcing initiative to test how well the effects of a toxic compound can be predicted in different ...
DeepBind predicts where proteins bind, uncovering disease-causing mutations
A new tool called DeepBind uses deep learning to analyze how proteins bind to DNA and RNA, allowing it to detect mutations that could disrupt cellular processes and cause disease.
Novel glycoengineering technology gives qualitative leap for biologics drug research
Researchers from the University of Copenhagen have discovered a way of improving biotech drugs. Better, cheaper and more effective drugs to combat cancer, arthritis and many other disorders.
New tech could find tiny RNA cancer beacons in blood
Cancerous tumors cast off tiny telltale genetic molecules known as microRNAs and University of Michigan researchers have come up with an efficient way to detect them in blood.
The hidden treasure in RNA-seq
Michael Stadler and his team at the Friedrich Miescher institute for Biomedical Research (FMI) have developed a novel computational approach to analyze RNA-seq data. By comparing intronic and exonic RNA reads, this approach ...
Better mouse model enables colon cancer research
Every day, it seems, someone in some lab is "curing cancer." Well, it's easy to kill cancer cells in a lab, but in a human, it's a lot more complicated, which is why nearly all cancer drugs fail clinical trials.
'Measuring stick' standard for gene sequencing now available from NIST
The world's first reference material to help ensure laboratories accurately "map" DNA for genetic testing, medical diagnoses and future customized drug therapies is now available from the National Institute of Standards and ...
Pulling the strings of our genetic puppetmasters: Engineers gain control of gene activity
Duke researchers have developed a new method to precisely control when genes are turned on and active.
Using CRISPR, biologists find a way to comprehensively identify anti-cancer drug targets
Imagine having a complete catalog of the best drug targets to hit in a particularly deadly form of cancer. Imagine having a master catalog of such targets for all the major cancer types and subtypes. Scientists at Cold Spring ...
Chinese researchers present de novo assembly of a haplotype-resolved diploid genome
Researchers from BGI reported the most complete haploid-resolved diploid genome (HDG) sequence based on de novo assembly with NGS technology and the pipeline developed lays the foundation for de novo assembly of genomes with ...